-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia-
GENEVA, Switzerland and BOSTON- July2, 2021 - ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant, an oral prostaglandin F2alpha (PGF2a) antagonist, for the treatment of spontaneous preterm labor at the Society for Reproductive Investigation (SRI) 68th Annual Meeting, being held virtually and in Boston July 6 -9, 2021.
Presentation detailsare as follows:
Title: A Randomized, Placebo-Controlled, Proof-of-Concept Trial of Ebopiprant for the Treatment of Spontaneous Preterm Labor (PROLONG)
Abstract ID: W-063
Poster Session: Clinical Perinatology
Presenter: Elizabeth Garner, M.D., M.P.H., Chief Medical Officer of ObsEva
Session Date: Wednesday, July 7, 2021
Session Time: 4:00-5:30 p.m. ET
Title: Pharmaceutical Industry Development in Preterm Labor Treatment: Current Landscape
Mini Symposia II: Update on Diagnostics and Therapeutics for Preterm Birth
Presenter: Elizabeth Garner, M.D., M.D.H., Chief Medical Officer of ObsEva
Session Date: Thursday, July 8, 2021
Session Time: 5:35-6:00 p.m. ET
The link to the session will be available under "Events Calendar" in the Investors section of ObsEva's website at www.ObsEva.com
About Ebopiprant and PGF2a
ObsEva is developing ebopiprant, a potential first-in-class, once daily, oral and selective prostaglandin F2a receptor antagonist, which is designed to control preterm labor by reducing inflammation, decreasing uterine contractions, preventing cervical changes and fetal membrane rupture without causing the potentially serious side effects to the fetus seen with non-specific prostaglandin synthesis inhibitors (NSAIDs). PGF2a is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture. In nonclinical studies, ObsEva has observed that ebopiprant markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with non-specific prostaglandin inhibitors such as indomethacin. Ebopiprant (OBE022) was licensed from Merck KGaA, Darmstadt, Germany, in 2015. ObsEva retains worldwide, exclusive, commercial rights.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol "OBSN". For more information, please visit www.ObsEva.com.
Cautionary Note Regarding Forward Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", and similar expressions, and are based on ObsEva's current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of and commercialization plans for ObsEva's product candidates, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA and ObsEva's ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva's reliance on third parties over which it may not always have full control, the impact of the ongoing novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva's Annual Report on Form 20-F for the year ended December 31, 2020 filed with Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact:
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617)-435-6602
Attachment
- Press Release in Pdf (https://ml-eu.globenewswire.com/Resource/Download/af75e168-1a97-4944-81ba-a29d0d60e80c)
